NKTR – Nektar Therapeutics

Float Short %

9.06

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

-0.72

EPS Last/This Y

-2.89

EPS This/Next Y

-0.27

Price

53.3

Target Price

107.29

Analyst Recom

1.22

Performance Q

6.84

Relative Volume

0.51

Beta

-0.95

Ticker: NKTR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	NKTR	59.5	0.59	0.56	50308
2025-11-18	NKTR	59.14	0.57	0.08	49336
2025-11-19	NKTR	60.42	0.58	0.15	48944
2025-11-20	NKTR	55.18	0.59	0.48	48404
2025-11-21	NKTR	53.64	0.58	0.48	47846
2025-11-24	NKTR	58.64	0.25	0.25	22653
2025-11-25	NKTR	60.39	0.25	0.47	23148
2025-11-26	NKTR	65.71	0.24	0.09	23185
2025-12-01	NKTR	61.33	0.25	0.27	25588
2025-12-02	NKTR	54.91	0.25	0.38	25904
2025-12-03	NKTR	57.19	0.27	0.39	26811
2025-12-04	NKTR	57.68	0.28	0.38	28448
2025-12-05	NKTR	56.85	0.27	0.09	28948
2025-12-08	NKTR	57.2	0.27	0.31	29476
2025-12-09	NKTR	58.78	0.27	0.46	29908
2025-12-10	NKTR	57.62	0.27	0.11	30524
2025-12-11	NKTR	51.07	0.27	0.56	30872
2025-12-12	NKTR	54.83	0.29	0.47	31232
2025-12-15	NKTR	53.3	0.29	0.30	31838
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-17	NKTR	59.23	-32.2	-	-7.97
2025-11-18	NKTR	59.15	-32.2	-	-7.97
2025-11-19	NKTR	60.35	-32.2	-	-7.97
2025-11-20	NKTR	55.17	-32.2	-	-7.97
2025-11-21	NKTR	54.18	-46.2	-	-9.78
2025-11-24	NKTR	58.69	-46.2	-	-9.78
2025-11-25	NKTR	60.35	-46.2	-	-9.78
2025-11-26	NKTR	65.72	-46.2	-	-9.78
2025-12-01	NKTR	61.10	-22.1	-	-9.88
2025-12-02	NKTR	54.85	-22.1	-	-9.88
2025-12-03	NKTR	57.13	-22.1	-	-9.88
2025-12-04	NKTR	57.57	-22.1	-	-9.88
2025-12-05	NKTR	56.90	-46.2	-	-9.78
2025-12-08	NKTR	57.28	-46.2	-	-9.78
2025-12-09	NKTR	58.78	-46.2	-	-11.59
2025-12-10	NKTR	57.69	-46.2	-	-11.59
2025-12-11	NKTR	51.10	-46.2	-	-11.59
2025-12-12	NKTR	54.70	-46.2	-	-11.59
2025-12-15	NKTR	53.30	-46.2	-	-11.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-17	NKTR	-13.48	17.68	7.40
2025-11-18	NKTR	-13.48	17.68	7.40
2025-11-19	NKTR	-13.48	17.68	7.40
2025-11-20	NKTR	-13.48	17.68	7.40
2025-11-21	NKTR	-13.48	17.68	7.40
2025-11-24	NKTR	-5.37	41.58	7.34
2025-11-25	NKTR	-8.12	41.58	7.34
2025-11-26	NKTR	-9.29	41.58	9.04
2025-12-01	NKTR	-9.29	41.55	9.04
2025-12-02	NKTR	-9.06	41.55	9.04
2025-12-03	NKTR	-9.06	41.55	9.04
2025-12-04	NKTR	-9.06	41.55	9.04
2025-12-05	NKTR	-9.06	41.55	9.04
2025-12-08	NKTR	-9.06	41.14	9.04
2025-12-09	NKTR	-9.06	41.14	9.04
2025-12-10	NKTR	-9.06	41.14	9.07
2025-12-11	NKTR	-9.06	41.14	9.07
2025-12-12	NKTR	-9.06	41.14	9.07
2025-12-15	NKTR	-9.06	41.12	9.06
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="NKTR" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-1.87

Avg. EPS Est. Current Quarter

-3.29

Avg. EPS Est. Next Quarter

-2.59

Insider Transactions

-9.06

Institutional Transactions

41.12

Beta

-0.95

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.7

Max Drawdown 5-Year %

-98.3

Target Price

107.29

P/E

Forward P/E

PEG

P/S

17.32

P/B

12.31

P/Free Cash Flow

EPS

-7.94

Average EPS Est. Cur. Y

-11.59

EPS Next Y. (Est.)

-11.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-192.87

Relative Volume

0.51

Return on Equity vs Sector %

-168.9

Return on Equity vs Industry %

-153.8

EPS 1 7Days Diff

-11.6

EPS 1 30Days Diff

-0.98

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”NKTR” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NKTR” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NKTR” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NKTR” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NKTR” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NKTR” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NKTR” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

NKTR – Nektar Therapeutics

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y